top of page

SEMAGLUTIDE for Weight Loss

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that has shown remarkable effectiveness in promoting weight loss. It works by regulating appetite and food intake, leading to significant and sustained weight reduction.

Mechanism of Action: Semaglutide mimics the GLP-1 hormone, which is crucial for appetite control. It works by:

  • Enhancing insulin secretion in response to meals

  • Suppressing glucagon release, which reduces hepatic glucose production

  • Slowing gastric emptying, leading to prolonged satiety and reduced appetite


These combined effects help reduce calorie intake and promote weight loss.

Semaglutide’s efficacy in weight loss has been demonstrated in several clinical trials, particularly the STEP trials:

  1. STEP 1:

    • Participants: Individuals with a BMI ≥30 or ≥27 with at least one weight-related comorbidity (excluding diabetes).

    • Results: Participants receiving Semaglutide 2.4 mg once weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group.

  2. STEP 2:

    • Participants: Individuals with type 2 diabetes and a BMI ≥27.

    • Results: Participants receiving Semaglutide 2.4 mg once weekly lost an average of 9.6% of their body weight over 68 weeks, compared to 3.4% in the placebo group.

  3. STEP 3 and 4:

    • These trials further confirmed the efficacy of Semaglutide in weight management, showing significant weight reductions and improvements in cardiometabolic risk factors.


Safety Profile: Semaglutide is generally well-tolerated, with the most common side effects being gastrointestinal, such as nausea, vomiting, diarrhea, and constipation. These symptoms are usually mild to moderate and tend to decrease over time. Serious but rare side effects may include pancreatitis, gallbladder issues, and kidney problems.

Administration: Semaglutide is administered as a subcutaneous injection once a week. It can be injected into the abdomen, thigh, or upper arm. Proper injection technique and schedule should be followed as instructed by a healthcare provider.

Semaglutide is a highly effective medication for weight management, with substantial clinical evidence supporting its ability to achieve significant and sustained weight loss. It offers a promising option for individuals struggling with obesity or overweight with weight-related comorbidities. Discuss with your healthcare provider to determine if Semaglutide is right for you and to understand the potential risks and benefits.


U.S. Board Certified Providers

Partnered with Quest labs

HIPAA Compliant

1000+ REAL transformations

Weight loss solutions delivered to your door

Image by Catalin Pop

Easy three step process

1.  Fill out quick online form, to see if you qualify and schedule free consultation

2.  Once approved by our medical providers, you will receive your treatment plan

3.  You receive your medication and supplies to your doorstep!

Get started today!

Join our fitness program to get energized and feel rejuvenated.


What is the difference between Semaglutide and Tirzepatide? Semaglutide, a GLP-1 receptor agonist, promotes weight loss by increasing insulin secretion, reducing appetite, and slowing gastric emptying, resulting in effective appetite control and calorie reduction. Tirzepatide, with its dual action on GIP and GLP-1 receptors, not only enhances these effects but also significantly improves insulin sensitivity. This dual mechanism offers a more robust approach to weight loss, potentially leading to greater and more sustained weight reduction compared to Semaglutide.

Who is eligible for these medications? Adults with a BMI of 30 kg/m² or greater (obesity) Adults with a BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia)

What are potential side effects of these medications? Common side effects include nausea, vomiting, diarrhea, and constipation, while less common effects are abdominal pain, indigestion, and fatigue. Serious side effects, though rare, may include pancreatitis, gallbladder issues such as gallstones, kidney problems, and allergic reactions. Discuss these potential side effects with your healthcare provider before starting treatment.

How much weight can I expect to lose? For Semaglutide, the STEP trials demonstrated an average weight loss of around 15% of body weight over 68 weeks in adults with obesity or overweight with weight-related conditions. Participants also saw improvements in cardiovascular health markers and glycemic control. For Tirzepatide, the SURPASS trials indicated even greater weight loss, with participants losing up to 20% of their body weight over 72 weeks. Additionally, Tirzepatide showed improvements in insulin sensitivity, lipid profiles, and other metabolic health markers. These results highlight the potential for substantial weight reduction and overall health improvement with both medications. It is important to discuss with your healthcare provider to determine the best option for your individual needs.

How are these medications taken? Both Semaglutide and Tirzepatide are taken as subcutaneous injections, administered once a week. These injections can be self-administered in the abdomen, thigh, or upper arm. It is important to follow your healthcare provider's instructions on the proper injection technique and schedule.

What are compounded medications? We offer compounded Semaglutide and Tirzepatide, featuring the same active ingredients as the commercial products Wegovy® and Mounjaro®/Zepbound™, respectively. Our unique formulations also include L-carnitine, which may assist in fat burning and enhance energy levels. Disclaimer: Compounded medications are not FDA-approved and should be discussed with your healthcare provider to understand the specific risks and benefits. While compounded in licensed pharmacies, these medications may not have the same safety and efficacy profiles as commercially available drugs.

bottom of page